Image default
Water News

4 Covid vaccine candidates in human trial stage, 1 in pre-clinical stage, govt tells Rajya Sabha

Four COVID-19 vaccine candidates are at different stages of human trials while one, developed byGenique Life Sciences, is in the advanced pre-clinical stage,Union Science and TechnologyMinister Jitendra Singh said on Tuesday. In a written response to a question in theRajya Sabha, Singh saidCadila Healthcare Ltd‘s DNA-based vaccine candidate is in phase three clinical trial. It has also submitted the interim data for emergency use authorisation.

Biological E Ltd’s vaccine candidate is also in phase three clinical trial.

Bharat Biotech International Ltd’s Adeno intranasal vaccine candidate is in phase three clinical trial, while Gennova Biopharmaceuticals Ltd’s mRNA-vaccine candidate is in Phase one clinical trial.

The Gurgaon-based Genique Life Sciences Pvt Ltd’s vaccine candidate is in the advanced pre-clinical stage, Singh said.

Currently, three vaccines — Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and Russian vaccine Sputnik V — are being administered in India.

Singh said ‘Mission COVID Suraksha — the Indian COVID-19 Vaccine Development Mission‘ was announced as part of the third stimulus package ‘Atmanirbhar Bharat 3.0’ for promoting research and development of Indian COVID-19 vaccines.

“The mission is supporting the development of four vaccine candidates in the clinical stage of development and one vaccine candidate in advance pre-clinical stage of development.

“The clinical development of vaccine candidates is being undertaken across the clinical trial sites situated pan-India,” he added.

(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.


Related posts

Government must indemnify vaccine makers against all lawsuits: Adar Poonawalla


Shot in the arm: Covid vaccine jab for those above 45 to start from tomorrow


India to scale up gene surveillance of SARS Cov2 in light of UK mutation


Leave a Comment